What's new? Log in Free sign up

BioNTech SE (BNTX)

Company Profile

Company profile

Ticker

BNTX

Exchange

Website

www.biontech.de

CEO

Dr. Ugur Sahin M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • Gladstone Investment ...

Former names

Bull Horn Holdings Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

BNTX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$142.22

Low target

$122.00

High target

$171.00

Evercore ISI Group

Canaccord Genuity

HC Wainwright & Co.

Morgan Stanley

Upgraded

Overweight

$145.00

24 Sep 24

Latest filings (excl ownership)

View all

Current report (foreign)

1 Welcome & Introductory Remarks Ryan Richardson, Chief Strategy Officer

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Current report (foreign)

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Current report (foreign)

BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart BNTX financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from BioNTech SE earnings reports.

Institutional ownership, Q3 2024

BNTX institutional ownership history Ownership history

79.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	298	287	+3.8%
Opened positions	77	35	+120.0%
Closed positions	66	38	+73.7%
Increased positions	72	84	-14.3%
Reduced positions	93	97	-4.1%

13F shares	Current	Prev Q	Change
Total value	5.08 tn	3.21 tn	+58.3%
Total shares	188.77 mm	188.70 mm	+0.0%
Total puts	2.29 mm	1.23 mm	+85.4%
Total calls	2.45 mm	845.10 k	+189.8%
Total put/call ratio	0.9	1.5	-36.0%

Largest owners	Shares	Value	Change
Athos KG	102.49 mm	$11.68 bn	-3.0%
Medine GmbH	41.41 mm	$0.00	0.0%
Baillie Gifford & Co	8.31 mm	$986.75 bn	+0.4%
FMR	6.30 mm	$748.24 bn	+797.8%
Primecap Management	4.52 mm	$536.43 bn	-5.7%
Flossbach Von Storch	4.36 mm	$517.79 bn	-0.5%
BLK BlackRock	2.07 mm	$246.08 bn	NEW
Temasek	1.81 mm	$214.64 bn	0.0%
Capital International Investors	1.02 mm	$121.28 bn	+37.4%
Capital International	930.47 k	$110.51 bn	+367.8%

Largest transactions	Shares	Bought/sold	Change
FMR	6.30 mm	+5.60 mm	+797.8%
Athos KG	102.49 mm	-3.12 mm	-3.0%
Harding Loevner	2.33 k	-2.92 mm	-99.9%
BLK BlackRock	2.07 mm	+2.07 mm	NEW
BLK BlackRock	0.00	-1.90 mm	EXIT
Capital World Investors	0.00	-955.98 k	EXIT
Capital International	930.47 k	+731.58 k	+367.8%
Millennium Management	24.10 k	-630.02 k	-96.3%
Fred Alger Management	500.84 k	+500.84 k	NEW
MS Morgan Stanley	675.92 k	-471.88 k	-41.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Critical Insights From BioNTech Analyst Ratings: What You Need To Know

Wells Fargo Initiates Coverage On BioNTech with Overweight Rating, Announces Price Target of $170

Wells Fargo analyst Mohit Bansal initiates coverage on BioNTech (NASDAQ:BNTX) with a Overweight rating and announces Price Target of $170.

Why Is BioNTech Stock Trading Higher On Friday?

BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients.

Reported Earlier, Duality Biologics And BioNtech Reveals Interim Results For B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 In Advanced Solid Tumors At ESMO Asia Congress 2024

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122

Press releases

From Benzinga Pro

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024

BNT324/DB-1311 showed encouraging antitumor activity and a manageable safety profile in a Phase 1/2a clinical trial in heavily pretreated patients with locally advanced or metastatic solid tumors, including small cell

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine candidate BNT113 based on BioNTech's FixVac platform Initiated two Phase 2 dose

BioNTech to Host Innovation Series R&D Day on November 14, 2024

BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.